Catalent Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey.

It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2019, it generated over $2.5 billion in annual revenue.

Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc. Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.

In 2014, Catalent became a public company and is listed on the New York Stock Exchange.

Traded as:           NYSE: CTLT; S&P 500 component

Industry:              Pharmaceuticals

Predecessor:     Cardinal Health PTS

Founded:            2007

Headquarters:   Somerset, New Jersey, U.S.

Services:              Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting

Website:              www.catalent.com